Aims: Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb-oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once-daily oral drug to treat sickle cell disease (SCD). This first-in-human study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of voxelotor in healthy volunteers and SCD patients.
SCD affects approximately 100 000 people in the United States and millions worldwide. 4, 5 Current approved treatments for SCD include hydroxyurea 6 and L-glutamine. 7 To date, no drugs have been approved that target the underlying mechanism of SCD. Hydroxyurea is not effective in some patients and has significant safety concerns, including potential embryofetal toxicity and myelosuppression. Lglutamine, recently approved, demonstrated only a modest effect in prevention of vaso-occlusive crisis without improvement in haematologic parameters, and does not target the pathophysiologic mechanism of disease. 8, 9 Therefore, a chronic preventive treatment remains a serious unmet need.
Because oxygenated Hb is a potent inhibitor of HbS polymerization, increasing the proportion of oxygenated HbS may provide a disease-modifying approach to SCD. [10] [11] [12] Previous Hb allosteric modifiers such as 5-hydroxymethylfurfural (5-HMF), 13 tucaresol, 14, 15 and valerosol (BW12C) 16 have been investigated. These agents (tucaresol and valerosol) demonstrated that increasing the Hb-oxygen affinity at 20-30% Hb modification inhibited RBC sickling in vitro and reduced haemolysis in SCD patients without compromising oxygen delivery to tissues. 17, 18 However, poor pharmaceutical properties (5-HMF), 17 lack of specificity, and immunogenicity (tucaresol 18 Following promising preclinical data, an "umbrella protocol"
(GBT440-001, NCT02285088) for a phase 1/2 study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), PD, PK-PD relationship, and effect of voxelotor on cardiovascular parameters at rest and during exercise following single and multiple doses of voxelotor administered to healthy volunteers and SCD patients. Dose selection and dose escalation were pharmacologically guided based on analysis of PD effect among cohorts.
Here, we report results of single and multiple doses of voxelotor in healthy volunteers and a single dose in SCD patients. Results of multiple dosing in SCD patients are published elsewhere. 22 2 | METHODS GBT440-001 was an integrated phase 1/2, two-centre, randomized, Table S1 . All subjects provided written informed consent before the commencement of any study-related procedures.
| Study design and treatment
An objective of this study was to demonstrate drug safety at high target percent Hb modification of~40% (RBC concentration of
What is already known about this subject
• Sickle cell disease affects millions of people worldwide and treatment remains a serious unmet need.
• Current approved treatments for sickle cell disease do not target the underlying pathophysiology of the disease.
• Haemoglobin oxygen affinity modulation to inhibit HbS polymerization is a promising and potentially diseasemodifying strategy for treating SCD.
What this study adds
• Once-daily dosing with voxelotor increases Hb oxygen affinity into a range that may be therapeutic for SCD patients.
• Voxelotor once-daily oral dosing demonstrated linear pharmacokinetics with dose-dependent increases in haemoglobin-oxygen affinity.
• Voxelotor was well tolerated with no dose-limiting toxicities or indications of tissue hypoxia.
675 μg mL −1 or 2 mM) in healthy volunteers, the level at which there was evidence of a compensatory increase in cardiac output with exercise from prior studies with other agents with similar mechanisms.
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To dose-escalate safely and effectively, a pharmacologically guided approach was implemented ( Figure 1 No formal power calculations were performed. The sample size was based on the desire to obtain adequate safety, tolerability, PK and PD data to achieve the objectives of the study whilst exposing as few subjects as possible to study medication and procedures.
| Part A: SAD
In each dose cohort, healthy volunteers were randomized to voxelotor (n = 6) or placebo (n = 2). Two sentinel subjects per cohort were dosed (one randomized to voxelotor and one randomized to placebo).
Providing there were no serious or unexplained safety issues, the remainder of the cohort were dosed 48 h later. 
| Pharmacokinetics
Serial blood samples were obtained for PK analyses for the determination of voxelotor concentrations in whole blood, plasma and RBCs.
Samples were analysed using a validated liquid chromatographytandem mass spectrometry method. Analytical ranges were 10-10 000 ng mL −1 and 5-5000 ng mL −1 for blood and plasma samples, respectively. Percent coefficients of variation (%CV) for lower limit of quantitation for intra-and inter-run was <11.8% for the whole FIGURE 1 Study design and dose-escalation scheme. Stepwise dose-escalation scheme for healthy volunteers and SCD patients. In each cohort, eight subjects were randomized to receive voxelotor (n = 6) or placebo (n = 2). Following the first dose, subsequent doses were escalated to reach 5%, 10% and 20% Hb modification. The first MAD cohort started after equivalent Hb modification was achieved in the single-dose cohort. The maximum target for the MAD cohort was 40% Hb modification. Food effect was evaluated at 400 mg. Single dose in SCD subjects was initiated at 1000 mg, and the data were used to estimate MAD doses at targeted 20% and 30% Hb modification blood method and <6.9% for the plasma method. Concentration of voxelotor in RBC was calculated from 23 :
| Pharmacodynamics
Percent Hb modification was determined by measuring the oxygen equilibrium curves (OECs) and changes in Hb-oxygen affinity using a TCS Hemox Analyzer. Clinical samples collected in sodium citrate vacutainers were kept at 4°C and analysed according to the method previously described 21 to obtain p20 and p50 values (partial pressure of O 2 at which Hb is 20% or 50% saturated with O 2 ). Delta p20 (Δ p20) and delta p50 (Δ p50) values were obtained by subtracting the day −1 from the sample value.
| Haematology and serum erythropoietin
Erythrocyte, reticulocyte, white blood cell and platelet counts were determined with a Siemens Advia 2120i (Siemens Healthcare Diagnostics, Surrey, UK). Serum erythropoietin (EPO) was measured by a chemiluminescent assay on a Siemens Immulite XPi (Siemens Healthcare Diagnostics, Surrey, UK).
| Exercise testing
Exercise testing was performed based on the Young Men's Christian
Association submaximal cycle ergometer test protocol. 24 Heart rate, respiratory rate, blood pressure and pulse oximetry (oxygen saturation) were evaluated.
| Statistical analysis
Demographic data were summarized by dose. PK, PD and safety data were summarized by dose and presented as summary statistics. p20 and p50 values between doses were compared using Sidak's multiple comparisons tests to measure statistical significance. PK/PD correlations were determined using linear regression.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 25 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18. 900 mg; n = 6 per group) or placebo (n = 2 per group; total n = 8). The demographics for these subjects are summarized in Table 1 . Mean age and body mass index were similar across the dosing groups. There was no apparent impact of race on any PK or PD parameters of voxelotor.
| Safety and tolerability
Following single doses, voxelotor was well tolerated up to and including the highest dose evaluated (2800 mg); i.e., a maximum tolerated single dose was not determined. Five treatment-emergent adverse events (TEAEs; diarrhoea, upper respiratory tract infection, arthralgia, headache and rash) were reported in >1 healthy volunteer (Table 2 ).
Of these, diarrhoea and headache were considered related to study drug. Diarrhoea occurred only at 2800 mg. In SCD patients receiving a single dose of 1000 mg voxelotor, four TEAEs (diarrhoea, nausea, vomiting and pain) were reported in >1 SCD patient (Table 3) . Of these, diarrhoea, nausea and vomiting were considered related to study drug. All AEs reported following a single dose of voxelotor in healthy volunteers and SCD patients were grade 1 (mild).
Following multiple doses, voxelotor was well tolerated up to and including the highest dose evaluated (900 mg daily for 15 days);
i.e., a maximum tolerated multiple dose was not determined. Five
TEAEs (abdominal pain, diarrhoea, gastroenteritis, dizziness and headache) were reported in ≥10% of healthy volunteers (Table 4) .
Headache, diarrhoea and abdominal pain were considered related to study drug. Most AEs were grade 1 in subjects receiving voxelotor;
all AEs were grade 1 in subjects receiving placebo. Three subjects who received voxelotor experienced grade 2 (moderate) events: one at 300 mg and two at 900 mg. No dose-limiting toxicities were identified. Two subjects discontinued study drug because of TEAEs; one subject receiving 600 mg discontinued on Day 12 because of a Single ascending dose in healthy volunteers 100 mg 400 mg 1000 mg 2000 mg 2800 mg All Placebo Preferred term n = 6 n = 6 n = 6 n = 6 n = 6 n = 30 n = 10 grade 1 rash and one subject receiving 900 mg discontinued on Day 7
because of a grade 2 headache along with grade 1 diarrhoea and abdominal pain. The rash was a typical and uncomplicated maculopapular rash. These events resolved without treatment except for headache, which was treated with paracetamol.
A theoretical concern with Hb-oxygen affinity modifiers is that they could reduce tissue oxygen delivery per unit volume of blood, resulting in a compensatory increase in EPO with subsequent reticulocytosis, increased RBC mass and increased cardiac output under conditions of exercise stress. 18, 27 To evaluate this concern, several specific assessments were performed including evaluation of reticulocyte counts, EPO levels and haemodynamic response to submaximal exercise testing. After multiple doses in healthy volunteers up to 900 mg daily, which achieved approximately 40% Hb modification, there was no evidence of a treatment-related increase in reticulocyte count or Hb level, EPO remained in the normal range (Figure 2) , and there was no increase in resting or peak exercise heart rate (data not shown).
| Pharmacokinetics
RBC and plasma concentration-time profiles of voxelotor following single dose (100-2800 mg) and multiple doses (300-900 mg), Day 15, in healthy volunteers are presented in Figure 3 . Comparison of RBC concentration-time profiles between healthy volunteers and SCD patients following 1000 mg are shown in Figure 4 . PK parameters are summarized in Table 5 . Following single dose administration to healthy volunteers, voxelotor was rapidly absorbed into the plasma with median T max < 4 h at doses <2000 mg. At 2800 mg, T max occurred later (7 h), likely because of continuing absorption of high drug load.
Later T max was observed in RBC (17-24 h 
| Pharmacodynamics
Blood samples collected from volunteers at various timepoints during both SAD and MAD studies were used to determine changes in Hb-oxygen affinity via OEC measurement. As the dose increased, both the p20 and p50 values decreased indicating an increase in Hb-oxygen affinity (Table 6 ). to <15% Hb modification, Figures 5 and 7D ). Based on a previously established in vitro correlation ( Figure S1 , Table S2 ), percent Hb modification was calculated from the Δp20 values and are summarized in Table 6 . The mean percent Hb modifications at 24 h following a single dose of 100, 400, 1000, 2000 and 2800 mg voxelotor were TABLE 6 PD parameters in healthy volunteers and SCD patients FIGURE 5 PD at steady state in healthy volunteers. A, Selected median OECs from subjects at C min after 15 days of dosing. A summary of the p20 (B) and p50 (C) values observed in healthy volunteers at C min after 15 days of dosing. A dose-dependent decrease in p20 and p50 was observed, showing that increasing levels of drug leads to increased Hb-oxygen affinities. Sidak's multiple comparisons tests were used to measure statistical significance (Table 6 ). In SCD, because of the anaemia, RBCs tend to have a higher 2,3-bisphosphoglycerate concentration leading to a lower Hb-oxygen affinity, and a rightward shifted OEC. Figure 6 shows the OEC for a predosed SCD patient, compared with the 24-h OEC post 1000 mg voxelotor dose, which exhibits a leftward shifted OEC, trending towards the OEC of a healthy volunteer. Figure 7B shows the correlation between Δp20 and RBC voxelotor concentrations in samples from healthy volunteers. These correlations allow for an estimation of the Hb-oxygen affinity in future studies when only the RBC voxelotor levels are available. Figure 7C shows a linear and robust correlation between p20 values and RBC levels of voxelotor (R 2 = 0.65). As expected, the correlation with p50 values is less robust (R 2 = 0.23) ( Figure 7D ). However, when data from 0 to 15% Hb modification (derived from OECs) is omitted, the correlation is improved to R 2 = 0.45, indicating that correlations with p50 improve at higher percent Hb modifications. Voxelotor is mainly eliminated by metabolism in humans with <1%
| PK/PD correlations
of the dose administered excreted unchanged into urine. 29 The T 1/2 of voxelotor (~60 days) is much shorter than the T 1/2 of human RBC, 30 implying its binding to Hb is a reversible process and drug can be released from Hb before being further metabolized.
In healthy volunteers, the PK of voxelotor was linear between 100 and 2800 mg. Accumulation of voxelotor was also linear upon multiple Evaluation of EPO, exercise testing and haematologic parameters was consistent with maintenance of normal oxygen delivery during rest and exercise up to the exposures achieved in this study, indicating that the percent Hb modification achieved in this study did not impair the ability of Hb to deliver oxygen to tissues.
In this first-in-human study, the highest single dose studied in SCD patients (1000 mg) and healthy volunteers (2800 mg) was well 
